Intermediate Risk Non-Muscle Invasive Bladder Cancer
1 clinical trials · Condition
◉ Watch Intermediate Risk Non-Muscle Invasive Bladder Cancer
| Record | Firm | Date |
|---|---|---|
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (NCT06510374) | Ferring Pharmaceuticals | 2024-10-01 |
Track Intermediate Risk Non-Muscle Invasive Bladder Cancer automatically
Every clearance here is in the API, with alerts when new ones post.